 |
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
U.S. Centers for Disease Control and Prevention
• U.S. News
FDA Approves Hepatitis C Treatment Ribasphere
December 9, 2005 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. The Food and Drug Administration has approved the hepatitis C treatment Ribasphere, co-manufactured by Par Pharmaceutical Cos. and Three Rivers Pharmaceuticals LLC, the companies said Monday. FDA approved Ribasphere, which uses the active ingredient ribavirin, in 200 mg, 400 mg and 600 mg tablets for use with interferon alfa-2a to treat hepatitis C. Back to other news for December 9, 2005 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. Associated Press 12.05.2005
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. |
E-Mail
Printer Friendly
Glossary
Share
